205 related articles for article (PubMed ID: 2478982)
1. Efficacy of nadolol alone or in combination with a type IA antiarrhythmic drug in sustained ventricular tachycardia: a prospective study.
Munsif AN; Saksena S
Pacing Clin Electrophysiol; 1989 Nov; 12(11):1816-26. PubMed ID: 2478982
[TBL] [Abstract][Full Text] [Related]
2. Electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias.
Saksena S; Klein GJ; Kowey PR; Calvo RA; Boccadamo R; Brown JE; Sharma AD; Gadhoke A; Olukotun AY
Am J Cardiol; 1987 Feb; 59(4):307-12. PubMed ID: 3812280
[TBL] [Abstract][Full Text] [Related]
3. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans.
Sager PT; Nademanee K; Antimisiaris M; Pacifico A; Pruitt C; Godfrey R; Singh BN
Circulation; 1993 Sep; 88(3):1072-82. PubMed ID: 8353869
[TBL] [Abstract][Full Text] [Related]
4. Ethmozine: electrophysiology, hemodynamics, and antiarrhythmic efficacy in patients with life-threatening ventricular arrhythmias.
Dorian P; Echt DS; Mead RH; Lee JT; Lebsack CS; Winkle RA
Am Heart J; 1986 Aug; 112(2):327-33. PubMed ID: 3526852
[TBL] [Abstract][Full Text] [Related]
5. Beta blockers in combination with class I antiarrhythmic agents.
Deedwania PC; Olukotun AY; Kupersmith J; Jenkins P; Golden P
Am J Cardiol; 1987 Aug; 60(6):21D-26D. PubMed ID: 2442991
[TBL] [Abstract][Full Text] [Related]
6. Prolongation of ventricular refractoriness by class Ia antiarrhythmic drugs in the prevention of ventricular tachycardia induction.
Kus T; Costi P; Dubuc M; Shenasa M
Am Heart J; 1990 Oct; 120(4):855-63. PubMed ID: 2220538
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia.
Wichter T; Borggrefe M; Haverkamp W; Chen X; Breithardt G
Circulation; 1992 Jul; 86(1):29-37. PubMed ID: 1617780
[TBL] [Abstract][Full Text] [Related]
8. A prospective comparison of class IA, B, and C antiarrhythmic agents in combination with amiodarone in patients with inducible, sustained ventricular tachycardia.
Toivonen L; Kadish A; Morady F
Circulation; 1991 Jul; 84(1):101-8. PubMed ID: 1905591
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of propranolol added to a type I antiarrhythmic agent for sustained ventricular tachycardia secondary to coronary artery disease.
Friehling TD; Lipshutz H; Marinchak RA; Stohler JL; Kowey PR
Am J Cardiol; 1990 Jun; 65(20):1328-33. PubMed ID: 2343820
[TBL] [Abstract][Full Text] [Related]
10. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
[TBL] [Abstract][Full Text] [Related]
11. Comparison of class Ia/Ib versus class III antiarrhythmic drugs for the suppression of inducible sustained ventricular tachycardia associated with coronary artery disease.
Khalighi K; Peters RW; Feliciano Z; Shorofsky SR; Gold MR
Am J Cardiol; 1997 Sep; 80(5):591-4. PubMed ID: 9294987
[TBL] [Abstract][Full Text] [Related]
12. Electrocardiographic and electrophysiologic effects of pirmenol in ventricular tachycardia.
Estes NA; Gold R; Cameron J; Haffajee C; Marshall M; Mack K; Salem DN
Am J Cardiol; 1987 Jun; 59(16):20H-26H. PubMed ID: 3591711
[TBL] [Abstract][Full Text] [Related]
13. Antiarrhythmic efficacy of ethmozine in patients with ventricular tachycardia as determined by programmed electrical stimulation.
Miura DS; Wynn J; Torres V; Laux B; Keefe D; Somberg JC
Am Heart J; 1986 Apr; 111(4):661-6. PubMed ID: 3513503
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease.
Greenspan AM; Spielman SR; Webb CR; Sokoloff NM; Rae AP; Horowitz LN
Am J Cardiol; 1985 Aug; 56(4):277-84. PubMed ID: 4025166
[TBL] [Abstract][Full Text] [Related]
15. Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia.
Rothbart ST; Saksena S
Am J Cardiol; 1986 Apr; 57(11):941-6. PubMed ID: 3515898
[TBL] [Abstract][Full Text] [Related]
16. Role of combination drug therapy with a class IC antiarrhythmic agent and mexiletine for ventricular tachycardia.
Mendes L; Podrid PJ; Fuchs T; Franklin S
J Am Coll Cardiol; 1991 May; 17(6):1396-402. PubMed ID: 2016457
[TBL] [Abstract][Full Text] [Related]
17. Electrophysiologic effects and predictors of success of combination therapy with class Ia and Ib antiarrhythmic drugs for sustained ventricular arrhythmias.
Foster MT; Peters RW; Froman D; Shorofsky SR; Gold MR
Am J Cardiol; 1996 Jul; 78(1):47-50. PubMed ID: 8712117
[TBL] [Abstract][Full Text] [Related]
18. Proarrhythmic effects of antiarrhythmic drugs during programmed ventricular stimulation in patients without ventricular tachycardia.
Au PK; Bhandari AK; Bream R; Schreck D; Siddiqi R; Rahimtoola SH
J Am Coll Cardiol; 1987 Feb; 9(2):389-97. PubMed ID: 2433319
[TBL] [Abstract][Full Text] [Related]
19. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Dorian P; Newman D; Berman N; Hardy J; Mitchell J
J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant metoprolol improves efficacy of class I antiarrhythmic drugs in patients with inducible sustained monomorphic ventricular tachycardia.
Brodsky MA; Chough SP; Allen BJ; Capparelli EV; Orlov MV; Caudillo G
Am Heart J; 1992 Sep; 124(3):629-35. PubMed ID: 1514490
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
